Generic Rimonabant, a new fat control drug to be sold as Acomplia, has recently been approved by the EU and is currently available to patients in the UK.. The UK is, the very first place that Acomplia will be marketed, however it is likely to be a couple of years prior to the drug is available to the general public.

Generic Rimonabant targets visceral fatty tissue, a section of fatty tissue which forms around vital organs. Reducing this section of fatty tissue has been found to stop the production of dangerous substances (such as cholesterol), which prevent the body managing insulin. This essentially means that Generic Rimonabant can reduce the risk of diabetes and heart disease.

Generic Rimonabant is the anorectic anti-obesity, CB1 Cannabinoid receptor antagonist medicine. The many vital key of its effect is lessening in craving food. Developed by Sanofi-Aventis, Acomplia (generic rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works by alleviating endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endogenous cannabinoids, such as anadamide, increases appetite.

Sanofi developed the premise that if cannabinoids promote hunger cravings, alleviating cannabinoid receptors in the brain might reduce appetite. The main cannabinoid (CB1) receptors are believed to play a role in controlling food intake. To develop appropriate drugs against this target, the human cannabinoid receptor was initially cloned and then expressed in the body.

Only two drugs are approved for long-treatment of obesity. They are the lipase inhibitor orlistat, the leading medication for fat reduction, and sibutramine. Use of both drugs has been held back by side effects. In the prevailing market there is an obvious chance for an effective and well-tolerated anti-obesity drug. Although Acomplia (generic rimonabant) appeared efficacious, like previous anti-obesity drugs, safety matters have seen its withdrawal.